Cited by 596Bone health and osteoporosis researchBone health and treatmentsBone Metabolism and Diseases

The DOI matches its Crossref record; 168 of the 168 references it cites were found in a registry or an index.

Use of bone turnover markers in postmenopausal osteoporosis

Eastell, Richard, Szulc, Pawel·2017·The Lancet Diabetes & Endocrinology

Open this paper in CoChat — free account

Abstract

Bone turnover comprises two processes: the removal of old bone (resorption) and the laying down of new bone (formation). N-terminal propeptide of type I procollagen (PINP) and C-telopeptide of type I collagen (CTX-I) are markers of bone formation and resorption, respectively, that are recommended for clinical use. Bone turnover markers can be measured on several occasions in one individual with good precision. However, these markers are subject to several sources of variability, including feeding (resorption decreases) and recent fracture (all markers increase for several months). Bone turnover markers are not used for diagnosis of osteoporosis and do not improve prediction of bone loss or fracture within an individual. In untreated women, very high bone turnover marker concentrations suggest secondary causes of high bone turnover (eg, bone metastases or multiple myeloma). In people with osteoporosis, bone turnover markers might be useful to assess the response to anabolic and antiresorptive therapies, to assess compliance to therapy, or to indicate possible secondary osteoporosis. Much remains to be learnt about how bone turnover markers can be used to monitor the effect of stopping bisphosphonate therapy (eg, to identify a threshold above which restarting therapy should be considered). More studies are needed to investigate the use of bone turnover markers for assessment of the bone safety of new medications.

Integrity signals

Registry

Crossref · 10.1016/s2213-8587(17)30184-5

Cites

168 of 168 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Effect of Parathyroid Hormone (1-34) on Fractures and Bone Mineral Density in Postmenopausal Women with Osteoporosis
Neer, R. M., Arnaud, C. D., Zanchetta, J. R., Prince, R., Gaich, G. A., Reginster, J.-Y., Hodsman, A. B., Eriksen, E. F., Ish-Shalom, S., Genant, H. K., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105103441904 · Cited by 4,602
Atypical subtrochanteric and diaphyseal femoral fractures: Second report of a task force of the American Society for Bone and Mineral Research
Shane, E., Burr, D., Abrahamsen, B., Adler, R. A., Brown, T. D., Cheung, A. M., Cosman, F., Curtis, J. R., Dell, R., Dempster, D. W., et al. (2014) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1998 · Cited by 2,147
Diagnosis and Management of Osteonecrosis of the Jaw: A Systematic Review and International Consensus
Khan, A. A., Morrison, A. D., Hanley, D. A., Felsenberg, D., McCauley, L. K., O’Ryan, F., Reid, I. R., Ruggiero, S. L., Taguchi, A., Tetradis, S., et al. (2014) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2405 · Cited by 1,360
Self-citation
Romosozumab in Postmenopausal Women with Low Bone Mineral Density
McClung, M. R., Grauer, A., Boonen, S., Bolognese, M. A., Brown, J. P., Diez-Perez, A., Langdahl, B. L., Reginster, J.-Y., Zanchetta, J. R., Wasserman, S. M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1305224 · Cited by 1,258
Denosumab in postmenopausal women with low bone mineral density.
McClung, M. R., Lewiecki, E. M., Cohen, S. B., Bolognese, M. A., Woodson, G. C., Moffett, A. H., Peacock, M., Miller, P. D., Lederman, S. N., Chesnut, C. H., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa044459 · Cited by 1,228
Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards
for the IOF-IFCC Bone Marker Standards Working Group, Vasikaran, S., Eastell, R., Bruyère, O., Foldes, A. J., Garnero, P., Griesmacher, A., McClung, M., Morris, H. A., Silverman, S., et al. (2011) · Osteoporosis International · doi:10.1007/s00198-010-1501-1 · Cited by 1,212
Self-citation
Denosumab in men receiving androgen-deprivation therapy for prostate cancer
Smith, M. R., Egerdie, B., Toriz, N. H., Feldman, R., Tammela, T. L. J., Saad, F., Heracek, J., Szwedowski, M., Ke, C., Kupic, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809003 · Cited by 1,140
Atypical subtrochanteric and diaphyseal femoral fractures: Report of a task force of the american society for bone and mineral Research
Shane, E., Burr, D., Ebeling, P. R., Abrahamsen, B., Adler, R. A., Brown, T. D., Cheung, A. M., Cosman, F., Curtis, J. R., Dell, R., et al. (2010) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.253 · Cited by 1,116
American Association Of Clinical Endocrinologists, Associazione Medici Endocrinologi, And European Thyroid Association Medical Guidelines For Clinical Practice For The Diagnosis And Management Of Thyroid Nodules
Gharib, H., Papini, E., Paschke, R., Duick, D. S., Valcavi, R., Hegedűs, L. D., Vitti, P., Gharib, H., Papini, E., Paschke, R., et al. (2010) · Endocrine Practice · doi:10.4158/10024.gl · Cited by 1,087
Molecular Mechanisms Mediating Proliferation/Differentiation Interrelationships During Progressive Development of the Osteoblast Phenotype
Stein, G. S., & Lian, J. B. (1993) · Endocrine Reviews · doi:10.1210/edrv-14-4-424 · Cited by 1,058
Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis
Garnero, P., Sornay‐Rendu, E., Chapuy, M. C., & Delmas, P. D. (1996) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650110307 · Cited by 1,000
10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension
Bone, H. G., Wagman, R. B., Brandi, M. L., Brown, J. P., Chapurlat, R., Cummings, S. R., Czerwiński, E., Fahrleitner-Pammer, A., Kendler, D. L., Lippuner, K., et al. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30138-9 · Cited by 996
Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis
Miller, P. D., Hattersley, G., Riis, B. J., Williams, G. C., Lau, E. M. C., Russo, L. A. T., Alexandersen, P., Zerbini, C. A. F., Hu, M., Harris, A. G., et al. (2016) · JAMA · doi:10.1001/jama.2016.11136 · Cited by 882
Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody
Padhi, D., Jang, G. R., Stouch, B., Fang, L., & Posvar, E. L. (2010) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.173 · Cited by 786
The Effect of Teriparatide [Human Parathyroid Hormone (1–34)] Therapy on Bone Density in Men With Osteoporosis
ORWOLL, E. S., Scheele, W. H., Paul, S., Adámi, S., Syversen, U., Díez‐Pérez, A., Kaufman, J.-M., Clancy, A., & Gaich, G. A. (2003) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2003.18.1.9 · Cited by 773
The effect of 3 versus 6 years of Zoledronic acid treatment of osteoporosis: A randomized extension to the HORIZON-Pivotal Fracture Trial (PFT)
Black, D. M., Reid, I. R., Boonen, S., Bucci-Rechtweg, C., Cauley, J. A., Cosman, F., Cummings, S. R., Hue, T. F., Lippuner, K., Lakatos, P., et al. (2012) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1494 · Cited by 700
Self-citation
Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research
Adler, R. A., Fuleihan, G. E., Bauer, D. C., Camacho, P. M., Clarke, B. L., Clines, G. A., Compston, J. E., Drake, M. T., Edwards, B. J.-A., Favus, M. J., et al. (2015) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2708 · Cited by 689
Effects of Denosumab Treatment and Discontinuation on Bone Mineral Density and Bone Turnover Markers in Postmenopausal Women with Low Bone Mass
Bone, H. G., Bolognese, M. A., Yuen, C. K., Kendler, D. L., Miller, P. D., Yang, Y., Grazette, L. P., Martín, J. S., & Gallagher, J. C. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-1502 · Cited by 634
Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial
Leder, B. Z., Tsai, J. N., Uihlein, A. V., Wallace, P. M., Lee, H., Neer, R. M., & Burnett‐Bowie, S. M. (2015) · The Lancet · doi:10.1016/s0140-6736(15)61120-5 · Cited by 618
One Year of Alendronate after One Year of Parathyroid Hormone (1–84) for Osteoporosis
Black, D. M., Bilezikian, J. P., Ensrud, K. E., Greenspan, S. L., Palermo, L., Hue, T. F., Lang, T., McGowan, J., & Rosen, C. J. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050336 · Cited by 614
Regulation of bone formation by osteoclasts involves Wnt/BMP signaling and the chemokine sphingosine-1-phosphate
Pederson, L., Ruan, M., Westendorf, J. J., Khosla, S., & Oursler, M. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0805133106 · Cited by 556
Efficacy of Bazedoxifene in Reducing New Vertebral Fracture Risk in Postmenopausal Women With Osteoporosis: Results From a 3-Year, Randomized, Placebo-, and Active-Controlled Clinical Trial
Silverman, S. L., Christiansen, C., Genant, H. K., Vukičević, S., Zanchetta, J., de Villiers, T. J., Constantine, G. D., & Chines, A. A. (2008) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.080710 · Cited by 510
Bisphosphonates and Fractures of the Subtrochanteric or Diaphyseal Femur
Black, D. M., Kelly, M. P., Genant, H. K., Palermo, L., Eastell, R., Bucci-Rechtweg, C. M., Cauley, J. A., Leung, P., Boonen, S., Santora, A. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001086 · Cited by 507
Self-citation
Differential Effects of Teriparatide on BMD After Treatment With Raloxifene or Alendronate
Ettinger, B. B., Martín, S., Crans, G., & Pavo, I. J. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.040117 · Cited by 486
Exogenous Testosterone or Testosterone with Finasteride Increases Bone Mineral Density in Older Men with Low Serum Testosterone
Amory, J. K., Watts, N. B., Easley, K. A., Sutton, P. R., Anawalt, B. D., Matsumoto, A. M., Bremner, W. J., & Tenover, J. L. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031110 · Cited by 475
American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the Diagnosis and Treatment of Postmenopausal Osteoporosis
Watts, N. B., Bilezikian, J. P., Camacho, P. M., Greenspan, S. L., Harris, S. T., Hodgson, S. F., Kleerekoper, M., Luckey, M. M., McClung, M. R., Pessah‐Pollack, R., et al. (2010) · Endocrine Practice · doi:10.4158/ep.16.s3.1 · Cited by 442
The Microanatomy of Trabecular Bone Loss in Normal Aging Men and Women
Aaron, J. E., Makins, N. B., & Sagreiya, K. (1987) · Clinical Orthopaedics and Related Research · doi:10.1097/00003086-198702000-00038 · Cited by 427
Change in Bone Turnover and Hip, Non-Spine, and Vertebral Fracture in Alendronate-Treated Women: The Fracture Intervention Trial
Bauer, D. C., Black, D. M., Garnero, P., Hochberg, M. C., Ott, S. M., Orloff, J. J., Thompson, D. E., Ewing, S. K., Delmas, P. D., & for the Fracture Intervention Trial Study Group (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.040512 · Cited by 402
International Osteoporosis Foundation and International Federation of Clinical Chemistry and Laboratory Medicine Position on bone marker standards in osteoporosis
Vasikaran, S. D., Cooper, C. C., Eastell, R., Griesmacher, A., Morris, H. A., Trenti, T., & Kanis, J. А. (2011) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2011.602 · Cited by 384
Self-citation
Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1–34)] in postmenopausal osteoporosis
Cosman, F., Eriksen, E. F., Recknor, C. P., Miller, P. D., Guañabens, N., Kasperk, C. H., Papanastasiou, P., Readie, A., Rao, H., Gasser, J. A., et al. (2010) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.238 · Cited by 358
Use of CTX-I and PINP as bone turnover markers: National Bone Health Alliance recommendations to standardize sample handling and patient preparation to reduce pre-analytical variability
for the National Bone Health Alliance Bone Turnover Marker Project, Szulc, P., Naylor, K. E., Hoyle, N. R., Eastell, R., & Leary, E. T. (2017) · Osteoporosis International · doi:10.1007/s00198-017-4082-4 · Cited by 347
Self-citation
The Impact of Monitoring on Adherence and Persistence with Antiresorptive Treatment for Postmenopausal Osteoporosis: A Randomized Controlled Trial
Clowes, J. A., Peel, N. F. A., & Eastell, R. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030501 · Cited by 334
Self-citation
Effect of an Aromatase Inhibitor on BMD and Bone Turnover Markers: 2-Year Results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) Trial (18233230)
Eastell, R., Hannon, R. A., Cuzick, J. M., Dowsett, M., Clack, G., & Adams, J. E. (2006) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.060508 · Cited by 332
Self-citation
Effect of feeding on bone turnover markers and its impact on biological variability of measurements
Clowes, J. A., Hannon, R. A., Yap, T. S., Hoyle, N. R., Blumsohn, A., & Eastell, R. (2002) · Bone · doi:10.1016/s8756-3282(02)00728-7 · Cited by 297
Self-citation
Two Years of Denosumab and Teriparatide Administration in Postmenopausal Women With Osteoporosis (The DATA Extension Study): A Randomized Controlled Trial
Leder, B. Z., Tsai, J. N., Uihlein, A. V., Burnett‐Bowie, S. M., Zhu, Y., Foley, K., Lee, H., & Neer, R. M. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-4440 · Cited by 283
A Novel Tetracycline Labeling Schedule for Longitudinal Evaluation of the Short-Term Effects of Anabolic Therapy With a Single Iliac Crest Bone Biopsy: Early Actions of Teriparatide
Lindsay, R., Cosman, F., Zhou, H., Bostrom, M. P., Shen, V., Cruz, J. D., Nieves, J. W., & Dempster, D. W. (2006) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.051109 · Cited by 277
Bone Density, Microstructure and Strength in Obese and Normal Weight Men and Women in Younger and Older Adulthood
Evans, A. L., Paggiosi, M., Eastell, R., & Walsh, J. (2014) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2407 · Cited by 268
Self-citation
Bone turnover markers: use in osteoporosis
Naylor, K. E., & Eastell, R. (2012) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2012.86 · Cited by 266
Self-citation
Effects of denosumab on bone turnover markers in postmenopausal osteoporosis
Eastell, R., Christiansen, C., Grauer, A., Kutílek, Š., Libanati, C. R., McClung, M. R., Reid, I. R., Resch, H., Siris, E. S., Uebelhart, D., et al. (2010) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.251 · Cited by 261
Self-citation
The Effect of 6 versus 9 Years of Zoledronic Acid Treatment in Osteoporosis: A Randomized Second Extension to the HORIZON-Pivotal Fracture Trial (PFT)
Black, D. M., Reid, I. R., Cauley, J. A., Cosman, F., Leung, P., Lakatos, P., Lippuner, K., Cummings, S. R., Hue, T. F., Mukhopadhyay, A., et al. (2014) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2442 · Cited by 260
Self-citation
Bisphosphonates and risk of subtrochanteric, femoral shaft, and atypical femur fracture: A systematic review and meta-analysis
Gedmintas, L., Solomon, D. H., & Kim, S. C. (2013) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1893 · Cited by 256
Effects of denosumab on bone histomorphometry: The FREEDOM and STAND studies
Reid, I. R., Miller, P. D., Brown, J. P., Kendler, D. L., Fahrleitner‐Pammer, A., Valter, I., Maasalu, K., Bolognese, M. A., Woodson, G. C., Bone, H. G., et al. (2010) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.149 · Cited by 254
Denosumab or Zoledronic Acid in Postmenopausal Women With Osteoporosis Previously Treated With Oral Bisphosphonates
Miller, P. D., Pannacciulli, N., Brown, J. P., Czerwinski, E. J., Nedergaard, B. S., Bolognese, M. A., Malouf, J., Bone, H. G., Reginster, J., Singer, A. J., et al. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-1801 · Cited by 244
Effects of Intermittent Parathyroid Hormone Administration on Bone Mineralization Density in Iliac Crest Biopsies from Patients with Osteoporosis: A Paired Study before and after Treatment
Misof, B. M., Roschger, P., Cosman, F., Kurland, E. S., Tesch, W., Messmer, P., Dempster, D. W., Nieves, J. W., Shane, E. J., Fratzl, P., et al. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021988 · Cited by 237
Relations between histologic indices of bone formation: Implications for the pathogenesis of spinal osteoporosis
Parfitt, A. M., Villanueva, A. R., Foldes, J., & Rao, D. S. (1995) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650100319 · Cited by 231
Bone Metabolism After Bariatric Surgery
Yu, E. W.-Y. (2014) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2226 · Cited by 218
Biochemical markers of bone turnover: potential use in the investigation and management of postmenopausal osteoporosis
Szulc, P., & Delmas, P. D. (2008) · Osteoporosis International · doi:10.1007/s00198-008-0660-9 · Cited by 218
Self-citation
Calcitonin controls bone formation by inhibiting the release of sphingosine 1-phosphate from osteoclasts
Keller, J., Catala-Lehnen, P., Huebner, A. K., Jeschke, A., Heckt, T., Lueth, A., Krause, M., Koehne, T., Albers, J., Schulze, J., et al. (2014) · Nature Communications · doi:10.1038/ncomms6215 · Cited by 211
Abdominal fat is associated with lower bone formation and inferior bone quality in healthy premenopausal women: a transiliac bone biopsy study
Cohen, A., Dempster, D. W., Recker, R. R., Lappe, J. M., Zhou, H., Zwahlen, A., Müller, R., Zhao, B., Guo, X., Lang, T., et al. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-1047 · Cited by 206
Serum CrossLaps for monitoring the response in individuals undergoing antiresorptive therapy
Christgau, S., Bitsch-Jensen, O., Bjarnason, N. H., Henriksen, E. G., Qvist, P., Alexandersen, P., & Henriksen, D. B. (2000) · Bone · doi:10.1016/s8756-3282(00)00248-9 · Cited by 199
Pretreatment Levels of Bone Turnover and the Antifracture Efficacy of Alendronate: The Fracture Intervention Trial
Bauer, D. C., Garnero, P., Hochberg, M. C., Santora, A., Delmas, P. D., Ewing, S. K., & Black, D. M. (2006) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.051018 · Cited by 192
A Meta-Analysis of Reference Markers of Bone Turnover for Prediction of Fracture
IFCC-IOF Joint Working Group on Standardisation of Biochemical Markers of Bone Turnover, Johansson, H., Odén, A., Kanis, J. А., McCloskey, E. V., Morris, H. A., Cooper, C. C., & Vasikaran, S. D. (2014) · Calcified Tissue International · doi:10.1007/s00223-014-9842-y · Cited by 191
Early Changes in Biochemical Markers of Bone Formation Correlate with Improvements in Bone Structure during Teriparatide Therapy
Dobnig, H., Sipos, A. A., Jiang, Y., Fahrleitner‐Pammer, A., Ste‐Marie, L., Gallagher, J. C., Pavo, I. J., Wang, J., & Eriksen, E. F. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-1703 · Cited by 191
Severe Rebound-Associated Vertebral Fractures After Denosumab Discontinuation: 9 Clinical Cases Report
Lamy, O., Rodríguez, E. G., Stoll, D., Hans, D. B., & Aubry‐Rozier, B. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-3170 · Cited by 191
Low dietary potassium intakes and high dietary estimates of net endogenous acid production are associated with low bone mineral density in premenopausal women and increased markers of bone resorption in postmenopausal women
Macdonald, H. M., New, S. A., Fraser, W. D., Campbell, M., & Reid, D. M. (2005) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/81.4.923 · Cited by 187
Effect of Monitoring Bone Turnover Markers on Persistence with Risedronate Treatment of Postmenopausal Osteoporosis
Delmas, P. D., Vrijens, B., Eastell, R., Roux, C., Pols, H. A. P., Ringe, J. D., Grauer, A., Cahall, D. L., Watts, N. B., & on behalf of the Improving Measurements of Persistence on Actonel Treatment (IMPACT) Investigators (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1526 · Cited by 186
Self-citation
Determinants of Bone Loss in Elderly Men and Women: A Prospective Population-Based Study
Dennison, E. M., Eastell, R., Fall, C. H. D., Kellingray, S., Wood, P. J., & Cooper, C. C. (1999) · Osteoporosis International · doi:10.1007/s001980050244 · Cited by 183
Self-citation
Rapid and robust response of biochemical markers of bone formation to teriparatide therapy
Glover, S. J., Eastell, R., McCloskey, E. V., Rogers, A., Garnero, P., Lowery, J., Belleli, R., Wright, T. M., & John, M. R. (2009) · Bone · doi:10.1016/j.bone.2009.07.091 · Cited by 177
Self-citation
Response of bone turnover markers to three oral bisphosphonate therapies in postmenopausal osteoporosis: the TRIO study
Naylor, K. E., Jacques, R., Paggiosi, M., Gossiel, F., Peel, N. F. A., McCloskey, E. V., Walsh, J., & Eastell, R. (2015) · Osteoporosis International · doi:10.1007/s00198-015-3145-7 · Cited by 175
Self-citation
Biochemical Markers as Predictors of Rates of Bone Loss After Menopause
Rogers, A., Hannon, R., & Eastell, R. (2000) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2000.15.7.1398 · Cited by 172
Self-citation
Establishing a Reference Interval for Bone Turnover Markers in 637 Healthy, Young, Premenopausal Women From the United Kingdom, France, Belgium, and the United States
Glover, S. J., Gall, M., Schönborn‐Kellenberger, O., Wagener, M., Garnero, P., Boonen, S., Cauley, J. A., Black, D. M., Delmas, P. D., & Eastell, R. (2008) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.080703 · Cited by 167
Self-citation
PINP as a biological response marker during teriparatide treatment for osteoporosis
Krege, J. H., Lane, N. E., Harris, J. M., & Miller, P. D. (2014) · Osteoporosis International · doi:10.1007/s00198-014-2646-0 · Cited by 166
Bone metabolism and renal stone risk during International Space Station missions
Smith, S. M., Heer, M. A., Shackelford, L. C., Sibonga, J. D., Spatz, J., Pietrzyk, R. A., Hudson, E. K., & Zwart, S. R. (2015) · Bone · doi:10.1016/j.bone.2015.10.002 · Cited by 165
Age-Related Changes in Bone Turnover in Men
Fatayerji, D., & Eastell, R. (1999) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1999.14.7.1203 · Cited by 163
Self-citation
Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: Efficacy and safety results from a randomized open-label study
Roux, C., Hofbauer, L. C., Ho, P., Wark, J. D., Zillikens, M. C., Fahrleitner‐Pammer, A., Hawkins, F. G., Micaëlo, M., Minisola, S., Παπαϊωάννου, Ν., et al. (2013) · Bone · doi:10.1016/j.bone.2013.10.006 · Cited by 158
Does Diet-Induced Weight Loss Lead to Bone Loss in Overweight or Obese Adults? A Systematic Review and Meta-Analysis of Clinical Trials
Zibellini, J., Seimon, R. V., Lee, C. M., Gibson, A. A., Hsu, M. S., Shapses, S. A., Nguyen, T. V., & Sainsbury, A. (2015) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2564 · Cited by 157
Evidence-based guidelines for the use of biochemical markers of bone turnover in the selection and monitoring of bisphosphonate treatment in osteoporosis: a consensus document of the Belgian Bone Club
Bergmann, P., Body, J. J., Boonen, S., Boutsen, Y., Devogelaer, J. P., Goemaere, S., Kaufman, J. M., Reginster, J.-Y., Gangji, V., & Members of the Advisory Board on Bone Markers (2008) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2008.01911.x · Cited by 152
Bone turnover markers and prediction of fracture: A prospective follow-up study of 1040 elderly women for a mean of 9 years
Ivaska, K. K., Gerdhem, P., Väänänen, H. K., Åkesson, K., & Obrant, K. J. (2009) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.091006 · Cited by 149
New developments in biological markers of bone metabolism in osteoporosis
Garnero, P. (2014) · Bone · doi:10.1016/j.bone.2014.05.016 · Cited by 148
Biochemical Markers of Bone Turnover, Hip Bone Loss, and Fracture in Older Men: The MrOS Study
Bauer, D. C., Garnero, P., Harrison, S. L., Cauley, J. A., Eastell, R., Ensrud, K. E., & ORWOLL, E. S. (2009) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.090526 · Cited by 147
Self-citation
Monitoring of Alendronate Treatment and Prediction of Effect on Bone Mass by Biochemical Markers in the Early Postmenopausal Intervention Cohort Study1
Ravn, P., Hosking, D. J., Thompson, D. E., Cizza, G., Wasnich, R. D., McClung, M. R., Yates, A. J. P., Bjarnason, N. H., & Christiansen, C. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.7.5847 · Cited by 144
International Osteoporosis Foundation and European Calcified Tissue Society Working Group. Recommendations for the screening of adherence to oral bisphosphonates
Díez‐Pérez, A., Naylor, K. E., Abrahamsen, B., Agnusdei, D., Brandi, M. L., Cooper, C. C., Dennison, E. M., Eriksen, E. F., Gold, D. T., Guañabens, N., et al. (2017) · Osteoporosis International · doi:10.1007/s00198-017-3906-6 · Cited by 141
Self-citation
The Relationship between Bone Turnover and Body Weight, Serum Insulin-Like Growth Factor (IGF) I, and Serum IGF-Binding Protein Levels in Patients with Anorexia Nervosa1
Hotta, M., Fukuda, I., Sato, K., Hizuka, N., Shibasaki, T., & Takano, K. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.1.6321 · Cited by 140
Fracture Prediction After Discontinuation of 4 to 5 Years of Alendronate Therapy
Bauer, D. C., Schwartz, A. V., Palermo, L., Cauley, J. A., Hochberg, M. C., Santora, A., Cummings, S. R., & Black, D. M. (2014) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2014.1232 · Cited by 137
Changes in bone mass and bone turnover following tibial shaft fracture
Veitch, S. W., Findlay, S. C., Hamer, A. J., Blumsohn, A., Eastell, R., & Ingle, B. M. (2005) · Osteoporosis International · doi:10.1007/s00198-005-2025-y · Cited by 136
Self-citation
Reassessment of Fracture Risk in Women After 3 Years of Treatment With Zoledronic Acid: When is it Reasonable to Discontinue Treatment?
Cosman, F., Cauley, J. A., Eastell, R., Boonen, S., Palermo, L., Reid, I. R., Cummings, S. R., & Black, D. M. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-1971 · Cited by 132
Self-citation
Relationship of changes in total hip bone mineral density to vertebral and nonvertebral fracture risk in women with postmenopausal osteoporosis treated with once-yearly zoledronic acid 5 mg: The HORIZON-Pivotal Fracture Trial (PFT)
Jacques, R., Boonen, S., Cosman, F., Reid, I. R., Bauer, D. C., Black, D. M., & Eastell, R. (2012) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1644 · Cited by 129
Self-citation
Reference intervals for serum concentrations of three bone turnover markers for men and women
Michelsen, J., Wallaschofski, H., Friedrich, N., Spielhagen, C., Rettig, R., Ittermann, T., Nauck, M. A., & Hannemann, A. (2013) · Bone · doi:10.1016/j.bone.2013.09.010 · Cited by 127
Changes in Bone Resorption Across the Menopause Transition: Effects of Reproductive Hormones, Body Size, and Ethnicity
Sowers, M. R., Zheng, H. T., Greendale, G. A., Neer, R. M., Cauley, J. A., Ellis, J. E., Johnson, S., & Finkelstein, J. S. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-4113 · Cited by 126
Bone-turnover markers in fracture healing
Cox, G., Einhorn, T. A., Tzioupis, C. C., & Giannoudis, P. V. (2010) · Journal of Bone and Joint Surgery - British Volume · doi:10.1302/0301-620x.92b3.22787 · Cited by 120
Biochemical Markers of Bone Resorption Compared with Estimates of Bone Resorption from Radiotracer Kinetic Studies in Osteoporosis
Eastell, R., Colwell, A., Hampton, L., & REEVE, J. (1997) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1997.12.1.59 · Cited by 114
Self-citation
Influence of remodeling on the mineralization of bone tissue
Boivin, G., Farlay, D., Bala, Y., Doublier, A., Meunier, P. J., & Delmas, P. D. (2009) · Osteoporosis International · doi:10.1007/s00198-009-0861-x · Cited by 110
Bone turnover markers for osteoporotic status assessment? A systematic review of their diagnosis value at baseline in osteoporosis
Biver, E., Chopin, F., Coiffier, G., Funck‐Brentano, T., Bouvard, B., Garnero, P., & Cortet, B. (2011) · Joint Bone Spine · doi:10.1016/j.jbspin.2011.05.003 · Cited by 102
Are Biochemical Markers of Bone Turnover Representative of Bone Histomorphometry in 370 Postmenopausal Women?
Chavassieux, P., Portero-Muzy, N., Roux, J.-P., Garnero, P., & Chapurlat, R. D. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-2957 · Cited by 99
Alendronate produces greater effects than raloxifene on bone density and bone turnover in postmenopausal women with low bone density: results of EFFECT (EFficacy of FOSAMAX® versus EVISTA®Comparison Trial) International1
Sambrook, P. N., Geusens, P., Ribot, C. A., Solimano, J. A., Ferrer-Barriendos, J., Gaines, K. A., Verbruggen, N., & Melton, M. E. (2004) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2004.01317.x · Cited by 98
Bone turnover markers in Paget’s disease of the bone: A Systematic review and meta-analysis
Nofal, A. A., Altayar, O., Benkhadra, K., Agha, O. Q., Asi, N., Nabhan, M., Prokop, L. J., Tebben, P. J., & Murad, M. H. (2015) · Osteoporosis International · doi:10.1007/s00198-015-3095-0 · Cited by 95
An Association Between Abnormal Bone Turnover, Systemic Inflammation, and Osteoporosis in Patients With Chronic Pancreatitis: A Case-Matched Study
Duggan, S. N., Purcell, C., Kilbane, M. T., O’Keane, M., McKenna, M. J., Gaffney, P. R., Ridgway, P. F., Boran, G. P., & Conlon, K. C. (2015) · The American Journal of Gastroenterology · doi:10.1038/ajg.2014.430 · Cited by 95
Changes in Bone Mass and Bone Turnover Following Ankle Fracture
Ingle, B. M., Hay, S. M., Bottjer, H. M., & Eastell, R. (1999) · Osteoporosis International · doi:10.1007/s001980050247 · Cited by 93
Self-citation
Fracture risk reduction during treatment with teriparatide is independent of pretreatment bone turnover
Delmas, P. D., Licata, A., Reginster, J., Crans, G., Chen, P., Misurski, D. A., Wagman, R. B., & Mitlak, B. (2006) · Bone · doi:10.1016/j.bone.2006.02.003 · Cited by 93
Bone turnover markers and bone mineral density response with risedronate therapy: Relationship with fracture risk and patient adherence
Eastell, R., Vrijens, B., Cahall, D. L., Ringe, J. D., Garnero, P., & Watts, N. B. (2011) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.342 · Cited by 92
Self-citation
High bone turnover is associated with accelerated bone loss but not with increased fracture risk in men aged 50 and over: the prospective MINOS study
Szulc, P., Montella, A., & Delmas, P. D. (2007) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2007.077941 · Cited by 91
Self-citation
Comparison of monoclonal and polyclonal antibody-based immunoassays for osteocalcin: A study of sources of variation in assay results
Tracy, R. P., Andrianorivo, A., Riggs, B. L., & Mann, K. G. (1990) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650050506 · Cited by 91
Diurnal Rhythms of Bone Turnover Markers in Three Ethnic Groups
Redmond, J., Fulford, A. J. C., Jarjou, L., Zhou, B., Prentice, A., & Schoenmakers, I. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-1183 · Cited by 91
Reference intervals of bone turnover markers in healthy premenopausal women: Results from a cross-sectional European study
Eastell, R., Garnero, P., Audebert, C., & Cahall, D. L. (2012) · Bone · doi:10.1016/j.bone.2012.02.003 · Cited by 90
Self-citation
Switching of oral bisphosphonates to denosumab in chronic glucocorticoid users: A 12-month randomized controlled trial
Mok, C. C., Ho, L. Y., & Ma, K. M. (2015) · Bone · doi:10.1016/j.bone.2015.03.002 · Cited by 87
The Relationship between Bone Turnover and Body Weight, Serum Insulin-Like Growth Factor (IGF) I, and Serum IGF-Binding Protein Levels in Patients with Anorexia Nervosa
Hotta, M. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.85.1.200 · Cited by 87
Teriparatide for Idiopathic Osteoporosis in Premenopausal Women: A Pilot Study
Cohen, A., Stein, E. M., Recker, R. R., Lappe, J. M., Dempster, D. W., Zhou, H., Cremers, S., McMahon, D. J., Nickolas, T. L., Müller, R., et al. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-1172 · Cited by 86
Age-related reference intervals for bone turnover markers from an Australian reference population
Jenkins, N., Black, M. B., Paul, E. M., Pasco, J. A., Kotowicz, M. A., & Schneider, H. G. (2013) · Bone · doi:10.1016/j.bone.2013.04.003 · Cited by 83
Association between bone turnover rate and bone microarchitecture in men: The STRAMBO study
Chaitou, A. R., Boutroy, S., Vilayphiou, N., Munoz, F., Delmas, P. D., Chapurlat, R. D., & Szulc, P. (2010) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.124 · Cited by 80
Self-citation
Early changes in biochemical markers of bone turnover and their relationship with bone mineral density changes after 24 months of treatment with teriparatide
EUROFORS Study Group, Blumsohn, A., Marín, F., Nickélsen, T., Brixen, K., Sigurdsson, G. T., de la Vera, J. G., Boonen, S., Liu-Léage, S., Barker, C., et al. (2010) · Osteoporosis International · doi:10.1007/s00198-010-1379-y · Cited by 80
Self-citation
Inhibition of markers of bone resorption by consumption of vitamin D and calcium-fortified soft plain cheese by institutionalised elderly women
Bonjour, J., Benoit, V., Pourchaire, O., Ferry, M., Rousseau, B., & Souberbielle, J. (2009) · British Journal Of Nutrition · doi:10.1017/s0007114509371743 · Cited by 79
Biochemical assessment of bone turnover and bone fragility in men
Szulc, P., Kaufman, J., & Delmas, P. D. (2007) · Osteoporosis International · doi:10.1007/s00198-007-0407-z · Cited by 78
Self-citation
The benefits of a high-intensity aquatic exercise program (HydrOS) for bone metabolism and bone mass of postmenopausal women
Moreira, L. D. F., Fronza, F. C. A. O., dos Santos, R. N., Zach, P. L., Kunii, I. S., Hayashi, L. F., Teixeira, L. R., Kruel, L. F. M., & Castro, M. L. (2013) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-013-0509-y · Cited by 77
Effects of soccer vs swim training on bone formation in sedentary middle-aged women
Mohr, M., Helge, E. W., Petersen, L. F., Lindenskov, A., Weihe, P., Mortensen, J., Jørgensen, N. R., & Krustrup, P. (2015) · European Journal of Applied Physiology · doi:10.1007/s00421-015-3231-8 · Cited by 76
Relationship of Early Changes in Bone Resorption to the Reduction in Fracture Risk With Risedronate: Review of Statistical Analysis
Eastell, R., Hannon, R. A., Garnero, P., Campbell, M. J., & Delmas, P. D. (2007) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.07090b · Cited by 76
Self-citation
Effect of Age-Related Chronic Immobility on Markers of Bone Turnover
Chen, J. S., Cameron, I. D., Cumming, R. G., Lord, S. R., MARCH, L. M., Sambrook, P. N., Simpson, J. M., & Seibel, M. J. (2006) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.051014 · Cited by 75
Effects of short-term step aerobics exercise on bone metabolism and functional fitness in postmenopausal women with low bone mass
Wen, H.-J., Huang, T., Li, T. L., Chong, P. N., & Ang, B. S. (2016) · Osteoporosis International · doi:10.1007/s00198-016-3759-4 · Cited by 75
Prednisone affects inflammation, glucose tolerance, and bone turnover within hours of treatment in healthy individuals
Kauh, E. A., Mixson, L. A., Malice, M., Mesens, S., Ramael, S., Burke, J., Reynders, T., Dyck, K. V., Beals, C. R., Rosenberg, E., et al. (2011) · European Journal of Endocrinology · doi:10.1530/eje-11-0751 · Cited by 73
Intravenous ibandronate injections given every three months: a new treatment option to prevent bone loss in postmenopausal women
Stakkestad, J. A., Benevolenskaya, L. I., Stepan, J. J., Skag, A., Nordby, A., Oefjord, E., Burdeska, A., Jonkanski, I., & Mahoney, P. (2003) · Annals of the Rheumatic Diseases · doi:10.1136/ard.62.10.969 · Cited by 72
Comparison of two automated assays of BTM (CTX and P1NP) and reference intervals in a Danish population
Jørgensen, N. R., Møllehave, L. T., Hansen, Y. B. L., Quardon, N., Lylloff, L., & Linneberg, A. (2017) · Osteoporosis International · doi:10.1007/s00198-017-4026-z · Cited by 72
Biochemical effects of calcium supplementation in postmenopausal women: influence of dietary calcium intake
Fardellone, P., Brazier, M., Kamel, S., Guéris, J., Graulet, A., Liénard, J., & Sebert, J. (1998) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/67.6.1273 · Cited by 71
Serum and Urine Markers of Bone Metabolism During the Year After Hip Fracture
Yu-Yahiro, J. A., Michael, R. H., Dubin, N. H., Fox, K. M., Sachs, M., Hawkes, W., Hebel, J. R., Zimmerman, S. I., Shapiro, J. R., & Magaziner, J. (2001) · Journal of the American Geriatrics Society · doi:10.1046/j.1532-5415.2001.49177.x · Cited by 69
Goal-directed treatment of osteoporosis in Europe
Kanis, J. А., McCloskey, E. V., Branco, J., Brandi, M. L., Dennison, E. M., Devogelaer, J.-P., Ferrari, S., Kaufman, J., Papapoulos, S. E., Reginster, J., et al. (2014) · Osteoporosis International · doi:10.1007/s00198-014-2787-1 · Cited by 68
Tartrate-resistant acid phosphatase 5b is a marker of osteoclast number and volume in RAW 264.7 cells treated with receptor-activated nuclear κB ligand
Lv, Y., Wang, G., Xu, W., Tao, P., Lv, X., & Wang, Y. (2014) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2014.2071 · Cited by 67
Feeding and bone
Walsh, J., & Henriksen, D. B. (2010) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2010.06.020 · Cited by 66
The effects of switching daily teriparatide to oral bisphosphonates or denosumab in patients with primary osteoporosis
Ebina, K., Hashimoto, J., Kashii, M., Hirao, M., Kaneshiro, S., Noguchi, T., Tsukamoto, Y., & Yoshikawa, H. (2016) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-015-0731-x · Cited by 66
Official Positions for FRAX® Clinical Regarding Biochemical Markers
McCloskey, E. V., Vasikaran, S. D., & Cooper, C. C. (2011) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2011.05.008 · Cited by 65
High bone turnover elevates the risk of denosumab-induced hypocalcemia in women with postmenopausal osteoporosis
Ishikawa, K., Nagai, T., Sakamoto, K., Ohara, K., Eguro, T., Ito, H., Toyoshima, Y., Kokaze, A., Toyone, T., & Inagaki, K. (2016) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s123172 · Cited by 62
18F-fluoride PET as a noninvasive imaging biomarker for determining treatment efficacy of bone active agents at the hip: A prospective, randomized, controlled clinical study
Frost, M. L., Moore, A. E. B., Siddique, M. M., Blake, G. M., Laurent, D., Borah, B., Schramm, U., Valentin, M., Pellas, T. C., Marsden, P. K., et al. (2013) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1862 · Cited by 60
Serial Assessment of Serum Bone Metabolism Markers Identifies Women with the Highest Rate of Bone Loss and Osteoporosis Risk
Ivaska, K. K., Lenora, J., Gerdhem, P., Åkesson, K., Väänänen, H. K., & Obrant, K. J. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-1508 · Cited by 60
Denosumab versus zoledronic acid in patients previously treated with zoledronic acid
Anastasilakis, A. D., Pοlyzos, S. A., Gkiomisi, A. I., Saridakis, Z. G., Digkas, D., Bisbinas, I., Sakellariou, G. T., Παπαθεοδώρου, Α., Kokkoris, P., & Makras, P. (2015) · Osteoporosis International · doi:10.1007/s00198-015-3174-2 · Cited by 60
Free 25(OH)D and Calcium Absorption, PTH, and Markers of Bone Turnover
Aloia, J. F., Dhaliwal, R., Mikhail, M., Shieh, A., Stolberg, A., Ragolia, L., Fazzari, M. J., & Abrams, S. A. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-2548 · Cited by 60
BMD changes and predictors of increased bone loss in postmenopausal women after a 5-year course of alendronate
McNabb, B., Vittinghoff, E., Schwartz, A. V., Eastell, R., Bauer, D. C., Ensrud, K. E., Rosenberg, E., Santora, A. C., Barrett-Connor, E. L., & Black, D. M. (2013) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1864 · Cited by 57
Self-citation
Denosumab increases sublesional bone mass in osteoporotic individuals with recent spinal cord injury
Gifre, L., Vidal, J., Carrasco, J. L., Muxí, Á., Portell, E., Monegal, A., Guañabens, N., & Peris, P. (2015) · Osteoporosis International · doi:10.1007/s00198-015-3333-5 · Cited by 55
Comparative Effect of Zoledronic Acid Versus Denosumab on Serum Sclerostin and Dickkopf-1 Levels of Naive Postmenopausal Women With Low Bone Mass: A Randomized, Head-to-Head Clinical Trial
Anastasilakis, A. D., Pοlyzos, S. A., Gkiomisi, A. I., Bisbinas, I., Gerou, S., & Makras, P. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-1402 · Cited by 52
Potassium Bicarbonate Supplementation Lowers Bone Turnover and Calcium Excretion in Older Men and Women: A Randomized Dose-Finding Trial
Dawson‐Hughes, B., Harris, S. S., Palermo, N. J., Gilhooly, C. H., Shea, M. K., Fielding, R. A., & Ceglia, L. (2015) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2554 · Cited by 50
Mineral metabolism markers and the long-term risk of hip fracture: the cardiovascular health study.
Robinson-Cohen, C., Katz, R., Hoofnagle, A., Cauley, J., Furberg, C., Robbins, J., Chen, Z., Siscovick, D., de Boer, I. D., & Kestenbaum, B. (2011) · Journal of Clinical Endocrinology and Metabolism · doi:10.1210/jc.2010-2878 · Cited by 49
Early changes in biochemical markers of bone formation during teriparatide therapy correlate with improvements in vertebral strength in men with glucocorticoid-induced osteoporosis
Farahmand, P., Marín, F., Hawkins, F. G., Moericke, R., Ringe, J. D., Glüer, C.-C., Παπαϊωάννου, Ν., Minisola, S., Martínez, G., Solé, J. M. N., et al. (2013) · Osteoporosis International · doi:10.1007/s00198-013-2379-5 · Cited by 48
Risk factors for the development of osteoporosis after spinal cord injury. A 12-month follow-up study
Gifre, L., Vidal, J., Carrasco, J. L., Muxí, Á., Portell, E., Monegal, A., Guañabens, N., & Peris, P. (2015) · Osteoporosis International · doi:10.1007/s00198-015-3150-x · Cited by 46
Calcium supplementation and parathyroid hormone response to vigorous walking in postmenopausal women
SHEA, K. L., BARRY, D. W., SHERK, V. D., HANSEN, K. C., WOLFE, P., & KOHRT, W. M. (2014) · Medicine & Science in Sports & Exercise · doi:10.1249/mss.0000000000000320 · Cited by 46
The effect of postexercise carbohydrate and protein ingestion on bone metabolism
TOWNSEND, R., ELLIOTT-SALE, K. J., CURRELL, K., TANG, J., FRASER, W. D., & SALE, C. (2017) · Medicine & Science in Sports & Exercise · doi:10.1249/mss.0000000000001211 · Cited by 46
Risk factors for development of atypical femoral fractures in patients on long-term oral bisphosphonate therapy
Franceschetti, P., Bondanelli, M., Caruso, G., Ambrosio, M. R., Lorusso, V., Zatelli, M. C., Massari, L., & Uberti, E. C. D. (2013) · Bone · doi:10.1016/j.bone.2013.07.010 · Cited by 45
Association of bone turnover markers with volumetric bone loss, periosteal apposition, and fracture risk in older men and women: the AGES-Reykjavik longitudinal study
Marques, E. A., Gudnason, V. G., Lang, T., Sigurdsson, G. T., Sigurdsson, S. O., Aspelund, T., Siggeirsdóttir, K., Launer, L. J., Eiríksdóttir, G., & Harris, T. B. (2016) · Osteoporosis International · doi:10.1007/s00198-016-3675-7 · Cited by 43
Urinary N-telopeptide and Rate of Bone Loss Over the Menopause Transition and Early Postmenopause
Shieh, A., Ishii, S., Greendale, G. A., Cauley, J. A., Lo, J. C.-M., & Karlamangla, A. S. (2016) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2889 · Cited by 42
Evaluation of urinary N-telopeptide of type I collagen measurements in the management of osteoporosis in clinical practice
Baxter, I., Rogers, A., Eastell, R., & Peel, N. F. A. (2012) · Osteoporosis International · doi:10.1007/s00198-012-2097-4 · Cited by 40
Self-citation
The association between critical illness and changes in bone turnover in adults: a systematic review
Orford, N. R., Cattigan, C., Brennan-Olsen, S. L., Kotowicz, M. A., Pasco, J. A., & Cooper, D. J. (2014) · Osteoporosis International · doi:10.1007/s00198-014-2734-1 · Cited by 40
High bone turnover in the elderly
Theiler, R., Stähelin, H. B., Kränzlin, M., Tyndall, A., & Bischoff, H. A. (1999) · Archives of Physical Medicine and Rehabilitation · doi:10.1016/s0003-9993(99)90186-7 · Cited by 39
Teriparatide and denosumab combination therapy and skeletal metabolism
Idolazzi, L., Rossini, M., Viapiana, O., Braga, V., Fassio, A., Benini, C., Kunnathully, V., Adámi, S., & Gatti, D. (2016) · Osteoporosis International · doi:10.1007/s00198-016-3647-y · Cited by 38
Bone Metabolism in Anorexia Nervosa
Fazeli, P. K., & Klibanski, A. (2014) · Current Osteoporosis Reports · doi:10.1007/s11914-013-0186-8 · Cited by 37
Enhanced bone metabolism in vegetarians – the role of vitamin B12 deficiency
Herrmann, W., Obeid, R., Schorr, H., Hübner, U., Geisel, J., Sand-Hill, M., Ali, N., & Herrmann, M. (2009) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2009.302 · Cited by 37
Reference intervals for bone turnover markers in Spanish premenopausal women
Guañabens, N., Filella, X., Monegal, A., Gómez‐Vaquero, C., Bonet, M., Buquet, D., Casado, E., Cerdá, D., Erra, A., Martinez, S., et al. (2015) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2015-0162 · Cited by 37
L-Phenylalanine concentration in blood of phenylketonuria patients: a modified enzyme colorimetric assay compared with amino acid analysis, tandem mass spectrometry, and HPLC methods
Silva, V. D., Oldham, C. D., & May, S. W. (2010) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2010.271 · Cited by 35
Risk factors for development of Atypical Femoral Fractures in patients on long-term oral Bisphosphonate therapy
Cardoso, R., Genrinho, I., Silva, S. L., Mazeda, C., Vilas-Boas, P., Brenha, J., & Barcelos, A. (2022) · Bone Reports · doi:10.1016/j.bonr.2022.101477 · Cited by 35
Biochemical markers of bone turnover and clinical outcomes in men with prostate cancer
Fred Saad, C., Eastham, J. A., & Smith, M. R. (2010) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2010.08.007 · Cited by 34
Effect of high dietary sodium on bone turnover markers and urinary calcium excretion in Korean postmenopausal women with low bone mass
Park, S. M., Joung, J. Y., Cho, Y. Y., Sohn, S. Y., Hur, K. Y., Kim, J. H., Kim, S. W., Chung, J. H., Lee, M. ‐., & Min, Y. ‐. (2015) · European Journal of Clinical Nutrition · doi:10.1038/ejcn.2014.284 · Cited by 34
Potential Usefulness of BMD and Bone Turnover Monitoring of Zoledronic Acid Therapy Among Women With Osteoporosis: Secondary Analysis of Randomized Controlled Trial Data
Bell, K., Hayen, A. D., Glasziou, P., Irwig, L., Eastell, R., Harrison, S. L., Black, D. M., & Bauer, D. C. (2016) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2847 · Cited by 30
Self-citation
Effects of calcium-fortified ice cream on markers of bone health
Ferrar, L., van der Hee, R. M., Berry, M. J., Watson, C., Miret, S., Wilkinson, J., Bradburn, M. J., & Eastell, R. (2010) · Osteoporosis International · doi:10.1007/s00198-010-1513-x · Cited by 29
Self-citation
Lower P1NP serum levels: a predictive marker of bone loss after 1 year follow-up in premenopausal systemic lupus erythematosus patients
Seguro, L. P. C., Casella, C., Caparbo, V. F., Oliveira, R. M., Bonfá, A. C., Bonfá, E., & Pereira, R. M. R. (2014) · Osteoporosis International · doi:10.1007/s00198-014-2860-9 · Cited by 27
Effect of Oral Anticoagulant Treatment on Markers for Calcium and Bone Metabolism
Knapen, M. H. J., Hellemons, B. S. P., Langenberg, M., Knottnerus, J. A., Hamulyák, K., Price, P. A., & Vermeer, C. (2000) · Pathophysiology of Haemostasis and Thrombosis · doi:10.1159/000054146 · Cited by 27
Greater milk intake is associated with lower bone turnover, higher bone density, and higher bone microarchitecture index in a population of elderly Japanese men with relatively low dietary calcium intake: Fujiwara-kyo Osteoporosis Risk in Men (FORMEN) Study
Sato, Y., Iki, M., Fujita, Y., Tamaki, J., Kouda, K., Yura, A., Moon, J., Winzenrieth, R., Iwaki, H., Ishizuka, R., et al. (2015) · Osteoporosis International · doi:10.1007/s00198-015-3032-2 · Cited by 27
Comparison in bone turnover markers during early healing of femoral neck fracture and trochanteric fracture in elderly patients
Ikegami, S., Kamimura, M., Nakagawa, H., Takahara, K., Hashidate, H., Uchiyama, S., & Kato, H. (2009) · Orthopedic Reviews · doi:10.4081/or.2009.e21 · Cited by 27
Rapid Onset and Sustained Efficacy (ROSE) study: results of a randomised, multicentre trial comparing the effect of zoledronic acid or alendronate on bone metabolism in postmenopausal women with low bone mass
Hadji, P., Gamerdinger, D., Spieler, W., Kann, P. H., Loeffler, H., Articus, K., Moericke, R., & Ziller, V. (2011) · Osteoporosis International · doi:10.1007/s00198-011-1583-4 · Cited by 27
Association between the Healthy Eating Index and bone turnover markers in US postmenopausal women aged ≥45 y
Hamidi, M. S., Tarasuk, V. S., Corey, P., & Cheung, A. M. (2011) · American Journal of Clinical Nutrition · doi:10.3945/ajcn.110.009605 · Cited by 27
The efficacy of calcium supplementation alone in elderly Thai women over a 2-year period: a randomized controlled trial
Rajatanavin, R., Chailurkit, L., Saetung, S., Thakkinstian, A., & Nimitphong, H. (2013) · Osteoporosis International · doi:10.1007/s00198-013-2387-5 · Cited by 26
Dietary patterns in men and women are simultaneously determinants of altered glucose metabolism and bone metabolism
Langsetmo, L., Barr, S. I., Dasgupta, K., Berger, C., Kovács, C. S., Josse, R. G., Adachi, J. D., Hanley, D. A., Prior, J. C., Brown, J. P., et al. (2015) · Nutrition Research · doi:10.1016/j.nutres.2015.12.010 · Cited by 24
Biomarkers of bone turnover in diagnosis and therapy of osteoporosis
Bieglmayer, C., Dimai, H. P., Gasser, R. W., Kudlacek, S., Obermayer-Pietsch, B. M., Woloszczuk, W., Zwettler, E., & Griesmacher, A. (2012) · Wiener Medizinische Wochenschrift · doi:10.1007/s10354-012-0133-9 · Cited by 23
Relationship Between Pretreatment Rate of Bone Loss and Bone Density Response to Once-Yearly ZOL: HORIZON-PFT Extension Study
Eastell, R., Boonen, S., Cosman, F., Reid, I. R., Palermo, L., Cummings, S. R., & Black, D. M. (2014) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2361 · Cited by 23
Self-citation
A retrospective analysis of nonresponse to daily teriparatide treatment
Niimi, R., Kono, T., Nishihara, A., Hasegawa, M., Kono, T., & Sudo, A. (2016) · Osteoporosis International · doi:10.1007/s00198-016-3581-z · Cited by 22
Improvement of cancellous bone microstructure in patients on teriparatide following alendronate pretreatment
Fahrleitner‐Pammer, A., Burr, D. B., Dobnig, H., Stepan, J. J., Petto, H., Li, J., Krege, J. H., & Pavo, I. J. (2016) · Bone · doi:10.1016/j.bone.2016.05.004 · Cited by 22
Response of bone turnover markers to raloxifene treatment in postmenopausal women with osteopenia
Naylor, K. E., Jacques, R., Peel, N. F. A., Gossiel, F., & Eastell, R. (2016) · Osteoporosis International · doi:10.1007/s00198-016-3573-z · Cited by 18
Self-citation
Low calcium intake is associated with increased bone resorption in postmenopausal Japanese women: Yokogoshi Study
Nakamura, K., Saito, T., Yoshihara, A., Ishikawa, M., Tsuchiya, Y., Oshiki, R., Kobayashi, R., Maruyama, K., Hyodo, K., Nashimoto, M., et al. (2009) · Public Health Nutrition · doi:10.1017/s1368980009005084 · Cited by 17
Reducing glucocorticoid dosage improves serum osteocalcin in patients with rheumatoid arthritis—results from the TOMORROW study
Tada, M., Inui, K., Sugioka, Y., Mamoto, K., Okano, T., Koike, T., & Nakamura, H. (2015) · Osteoporosis International · doi:10.1007/s00198-015-3291-y · Cited by 11
Early Changes in Bone Specific Turnover Markers During the Healing Process After Vertebral Fracture
Hashidate, H., Kamimura, M., Nakagawa, H., Takahara, K., Ikegami, S., Uchiyama, S., & Kato, H. (2011) · The Open Orthopaedics Journal · doi:10.2174/1874325001105010032 · Cited by 11
Change in serum undercarboxylated osteocalcin concentration in bilaterally oophorectomized women
Yasui, T., Uemura, H., Tomita, J., Miyatani, Y., Yamada, M., Kuwahara, A., Matsuzaki, T., Maegawa, M., Miura, M., & Irahara, M. (2006) · Maturitas · doi:10.1016/j.maturitas.2006.09.002 · Cited by 10
Adherence to raloxifene therapy: assessment methods and relationship with efficacy
Finigan, J., Naylor, K. E., Paggiosi, M., Peel, N. F. A., & Eastell, R. (2013) · Osteoporosis International · doi:10.1007/s00198-013-2386-6 · Cited by 10
Self-citation
Comparison of clinical cut-points and treatment targets for urine NTX and plasma βCTX-I in osteoporosis
Chubb, S. A. P., Mandelt, C., & Vasikaran, S. D. (2015) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2015.12.002 · Cited by 9
Associations between Systemic Markers of Bone Turnover or Bone Mineral Density and Anti-Resorptive Agent-Related Osteonecrosis of the Jaw in Patients Treated with Anti-Resorptive Agents.
Tohashi, K., Nakabayashi, M., Kodani, I., Kidani, K., & Ryoke, K. (2016) · PubMed Central · Cited by 9
DIFFERENTIAL EF ECTS OF TERIPARATIDE ON BONE MINERAL DENSITY AFTER TREATMENT WITH RALOXIFENE OR ALENDRONATE
Ettinger, B. B., Martín, J. S., Crans, G., & Pavo, I. J. (2004) · Cited by 7

Sorted by citations

Bone Turnover Markers: Basic Biology to Clinical Applications
Schini, M., Vilaça, T., Gossiel, F., Salam, S., & Eastell, R. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnac031 · Cited by 439
Self-citation
Biomarkers of aging
Bao, H., Cao, J., Chen, M., Min, C., Chen, W., Chen, X., Chen, Y., Chen, Y., Chen, Y., Chen, Z., et al. (2023) · Science China Life Sciences · doi:10.1007/s11427-023-2305-0 · Cited by 402
Osteogenesis and aging: lessons from mesenchymal stem cells
Infante, A., & Rodríguez, C. I. (2018) · Stem Cell Research & Therapy · doi:10.1186/s13287-018-0995-x · Cited by 334
Guidelines for the management of osteoporosis and fragility fractures
Nuti, R., Brandi, M. L., Checchia, G., Di Munno, O., Dominguez, L., Falaschi, P., Fiore, C. E., Iolascon, G., Maggi, S., Michieli, R., et al. (2019) · Internal and Emergency Medicine · doi:10.1007/s11739-018-1874-2 · Cited by 328
Lactobacillus rhamnosus GG ameliorates osteoporosis in ovariectomized rats by regulating the Th17/Treg balance and gut microbiota structure
Guo, M., Liu, H., Yu, Y., Zhu, X., Xie, H., Wei, C., Mei, C., Shi, Y. W., Zhou, N., Qin, K., et al. (2023) · Gut Microbes · doi:10.1080/19490976.2023.2190304 · Cited by 296

See all 596

Authors: Eastell, R., & Szulc, P.
Affiliations: University of Sheffield (GB)
Corresponding author: Eastell, Richard
ORCID: Eastell, Richard
Venue: The Lancet Diabetes & Endocrinology
Publisher: Elsevier BV
Published: 2017-11
Volume: 5
Issue: 11
Pages: 908-923
ISSN: 2213-8587 (ISSN-L)
DOI: 10.1016/s2213-8587(17)30184-5
OpenAlex: W2733907025
Cited by: 594
References: 168
Citations by year: 2026: 62 · 2025: 94 · 2024: 89 · 2023: 82 · 2022: 92 · 2021: 75 · 2020: 47 · 2019: 32 · 2018: 18 · 2017: 3
FWCI: 4.97
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: The Lancet Diabetes & Endocrinology (publishedVersion)
PubMed (publishedVersion)
Funders: National Institute for Health and Care Research (NF-SI-0513-10073)
Medical Research Council (MR/K006312/1, MR/P020941/1)
Topics: Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
Health Sciences › Medicine › Oncology › Bone health and treatments
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
Keywords: bone turnover markers, postmenopausal osteoporosis, bone resorption, bone formation, P1NP, C-terminal telopeptide of type I collagen, secondary osteoporosis, fracture risk prediction
MeSH terms: Diphosphonates, Humans, Biomarkers, Bone Density, Osteoporosis, Postmenopausal, Bone Remodeling, Fracture Healing, Bone Density Conservation Agents

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Use of bone turnover markers in postmenopausal osteoporosis

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks